NewCelX Ltd. (NCEL) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$2.45

From 52W high−54.24%

Volume233661.00

Market cap$14.96M

P/E (TTM)7.8x

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$2.45

From 52W high

−54.24%

Volume

233661.00

Market cap

$14.96M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.8x

P/E (TTM)

7.8x

RSI (14)

38.7

MomentumView details →

1D Return

−1.89%

YTD Return

+26.32%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

7.8x

EV/EBITDA

−3.8x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

23.93%

ROA (TTM)

14.90%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+100.90%

FCF YoY

+40.31%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+91.79%

EBITDA YoY

−0.76%

MomentumView details →

1D Return

−1.89%

YTD Return

+26.32%

1Y Return

−57.60%

RSI (14)

38.7

vs 50D SMA

−19.72%

vs 200D SMA

−22.65%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

0.32x

Quick Ratio

0.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

0.00%

Beats (12Q)

4/12

Next Q EPS Est

−$0.65

Avg Surprise (4Q)

73.48%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−720101.00

Op. CF (TTM)

−7.69M

Next earningsMar 3, 2027 →

Latest newsMore news →

NewcelX priced a $1.4 million private equity financing at a 20% premium to support its lead Type 1 Diabetes program.96d ago

Similar companies

Dyadic International, Inc.DYAI Bolt Biotherapeutics, Inc.BOLT Jasper Therapeutics, Inc.JSPR Citius Pharmaceuticals, Inc.CTXR Hoth Therapeutics, Inc.HOTH BioCardia, Inc.BCDA Find similar companies →

Latest newsMore news →

NewcelX priced a $1.4 million private equity financing at a 20% premium to support its lead Type 1 Diabetes program.96d ago